WhatFinger


The small Israeli pharma company NeuroRx is testing a novel compound of two existing drugs to quash suicidal feelings.

Hope for people with bipolar depression



More than three million Americans have bipolar depression, a condition that more than quintuples the risk of suicide compared with people who have other forms of clinical depression.

Support Canada Free Press


“Despite extensive evidence that 25 to 50 percent of those with bipolar depression attempt suicide and far too many succeed, there is currently no FDA-approved treatment for active suicidality in bipolar depression,” says Dr. Jonathan Javitt, a recent American immigrant to Israel and CEO of NeuroRx, a clinical-phase pharmaceutical company. Early this summer, NeuroRx reported its first human efficacy data for a newly purposed class of drugs aimed at rapidly reducing symptoms of depression and suicidality in patients with bipolar disorder and maintaining that effect over time. The seven treatment-resistant patients in the peer-reviewed study demonstrated a 50% reduction in symptoms of depression and a 75% reduction in suicidality after a regimen of the anesthetic drug ketamine followed by NeuroRx’s Cyclurad — a novel patent-pending combination of two FDA-approved pharmaceuticals, the tuberculosis drug D-cycloserine and the anti-infective drug lurasidone. More...


View Comments

Guest Column Israel21c -- Bio and Archives

Items of notes and interest from the web.


Sponsored